Project description
Advanced cell therapies for cancer
Cancer immunotherapy represents one of the most effective strategies to combat human malignancies, by harnessing the power of the immune system. However, despite the success in leukaemia, immune cell therapies against solid tumours have limited clinical success. Funded by the European Research Council, the CATACLIS project proposes to develop cellular products based on patient-specific characteristics. The project will leverage single-cell data from patients to improve T cell function and overcome issues associated with access to tumour tissue, antigen selection and immune suppression. The project is expected to yield novel cellular therapies tailored for individual patients.
Objective
"Cellular therapies are commonly used to treat hematological cancers but have yet to be established in solid oncology. Their evolution has been fuelled by hypotheses derived from cell biological observations in cancer models. Most approaches, however, will either never enter clinical development or fail clinical testing, often due to inadequate models of disease and their lack of relevance to human biology.
In CATACLIS, I propose the first unbiased development of cellular products based on patient characteristics in order to address this enormous translational gap and ultimately provide more effective cell therapies to patients with solid cancers. CATACLIS will herald a paradigm shift in cell therapy by reversing conventional model-to-patient innovation (""forward translation"") to patient-generated ideas tested in patient-derived models into clinical trials (""reverse translation"").
I have discovered novel approaches to improve T cell function, which resulted in a clinical trial and established me as a leader in the field of cellular therapies. The challenge I will now face is to move beyond model bias and integrate cancer heterogeneity across patients and entities. In CATACLIS, I will use single cell data sets from patients to inform the design of next generation cellular therapies capable of overcoming current limitations in solid cancers, namely 1) access to tumor tissue, 2) target antigen(s) selection, and 3) immune suppression. To maximize clinical relevance, CATACLIS will use patient-derived materials from hypothesis generation to in vivo testing. This will enable me to create cellular products tailored to the patient´s cancer
My research will not only result in novel cellular products for further testing and development toward clinical trials, but it will also serve as a resource for the development of innovative therapies based on patient data, contribute to the European open science objectives, and reduce the burden of animal experimentation.
"
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC - HORIZON ERC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2023-COG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
80539 MUNCHEN
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.